Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. - Wikidata - awgldk - TriplyDB

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.

http://www.wikidata.org/entity/Q43533227

about

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease Fabry disease in latin america: data from the fabry registry.Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina.The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).Use of lissamine rhodamine ceramide trihexoside as a functional assay for alpha-galactosidase A in intact cells Fabry disease: a survey of visual and ocular symptoms.Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry disease Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).Enzyme replacement therapy for Fabry disease: some answers but more questions Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications Update on role of agalsidase alfa in management of Fabry disease.Fabry disease: recent advances in enzyme replacement therapy.Hypertension in adult Fabry's disease: is cardiotrophin-1 a diagnostic biomarker?Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease Cellular and tissue distribution of intravenously administered agalsidase alfa.The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.Phenotype/genotype correlations in the ultrastructure of monogenetic glomerular diseases.Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy.Agalsidase benefits renal histology in young patients with Fabry disease.

P2860

Q24533551-9C498742-8C4D-4839-9A10-39DCFEDBBED6 Q24650910-64C1544C-A094-4921-916B-06251A6FD1F5 Q26752352-A270890A-01E8-41B0-924B-2571202B2A93 Q28250905-CB1DF926-4B3D-449B-9081-0938AEA5ABF4 Q28258153-CB5B3CDB-7E9D-497B-B331-13FE1B3B8CDE Q28477142-A3F10759-A16B-40F4-A080-E98B377D45DF Q28547115-BF4D2138-3BD0-4D4F-AA1A-74E445C84864 Q28727768-98226112-30CE-4FFF-AA79-813E2DCBE8F1 Q30501578-B3DDAFAD-8428-44F4-8987-2CD2F57BEB3A Q30592389-D24D0865-8393-48E8-A8C4-2F804BF66085 Q30983988-1FEC14FC-5C13-4912-9ED9-F76DCC46B965 Q33645550-538FA10C-2861-4018-A950-1D5E65659091 Q33683158-2271A962-51BE-4653-A8E8-BEB98C095CB1 Q33726258-A493DE5D-A2BD-4943-BCCA-C4B0F994F125 Q33730412-BAD9C8F5-2157-45EA-999A-5DF3FDFB7FA9 Q33737225-1A06FBBD-1309-4DAA-AF18-869F100FA456 Q33818578-AF61035C-6BB3-4E9F-83A0-6F7F6EA86588 Q33988780-9B3FC877-D3C3-444D-885F-C4F620771748 Q34053196-0AF927BC-A225-424C-95C2-7A8689EAB7C1 Q34093662-DBB227ED-1F7D-4AEF-ACF1-AC4C3B419AAB Q34360126-E9340AA8-625A-4D8B-8A39-1CB1343C27E8 Q34553589-2915A393-35DC-48B7-AF8E-727FD5076B3D Q34703815-CA4AB6C7-D182-42BF-BEDE-5AE25DE7E2B5 Q34805283-6EE2EACD-7EDF-4BB6-9F21-1EFE37C40523 Q34883178-EDAA3795-D1CF-4CEB-AACC-5FBB326ACB2D Q34974879-76942D45-087B-4877-8D2B-22718BE29D0B Q34976618-CBD3F0B8-3CA3-415B-A80A-5473EF4F5F3B Q35147741-DDD1F950-12B0-4B7A-BFB1-8F7E6608CB2E Q35207863-0105D6D5-E365-4596-A3A2-7176FF0DF6F8 Q35728693-5A19E747-1483-4A22-8B5A-BB4EF59937D0 Q35775374-F5A8CBE4-BB08-4DF9-97E3-564007983BE3 Q35842694-AC02C06C-D9E2-4F31-B992-662237468A4A Q35848678-ABFFD402-E627-4637-86D9-1227586CD6E9 Q35994824-9019E55E-CFED-4395-80C8-C41833C86DD8 Q36031348-6579FAFC-0413-434E-8946-81A6F1800877 Q36189989-C95D3E2C-5A10-49BC-A9BA-C25856AF72EC Q36213022-08FD0169-7E23-464D-B71A-0DA0BFBE8C44 Q36309032-9C9A421B-02A3-417C-A3FF-6099629F08B1 Q36315348-B47A68B5-CC8F-4B0A-8816-190034BB60A4 Q36509288-E79B8406-0380-4ADE-BF55-D8663A6DAA08

P2860

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.

http://www.wikidata.org/entity/Q43533227

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Natural history of Fabry renal ...... mutations on clinical course.

@en

Natural history of Fabry renal ...... mutations on clinical course.

@nl

type

label

Natural history of Fabry renal ...... mutations on clinical course.

@en

Natural history of Fabry renal ...... mutations on clinical course.

@nl

prefLabel

Natural history of Fabry renal ...... mutations on clinical course.

@en

Natural history of Fabry renal ...... mutations on clinical course.

@nl

P1433

Q43533227-4C8F1239-6A62-4EB0-AEC1-D89C3425A85D

P1476

Q43533227-3422A3AF-E77D-43B8-8455-49FFBDC3642C

P2093

Q43533227-2CB54819-7F9A-4203-9447-AE1F231AE4F7

Q43533227-3D4C36DF-ACF9-4C37-92E7-A5F52FCCC287

Q43533227-5A4B191F-15E7-4E9E-86C5-08D371E1D118

Q43533227-6CE6F991-F8C7-4B29-8666-338EDDD17D84

Q43533227-78DD9079-3F82-4C41-97D6-197D62D2CC72

Q43533227-B1D0E824-8426-43FE-8F56-873C96A3FD33

Q43533227-C2A0104E-0BD2-433F-BD62-FD30179A8182

Q43533227-C50837A4-E4E9-40B9-A997-E2995B78DE0C

Q43533227-CC6201E4-705F-4C3D-AE23-DE1E9000E82B

Q43533227-F34A286F-A214-4830-AD58-7EC3B94D04E3

P304

Q43533227-7E83991B-BC05-42A7-B562-C9095FA7E1F8

P31

Q43533227-16809A2F-72EF-479F-87D7-8454532F5819

P356

Q43533227-A7B67A29-9FF4-40D8-B6A3-70755526CB45

P407

Q43533227-36732355-02F4-403E-9B0C-0143D7839945

P433

Q43533227-1E814D5C-FC24-49E6-83C2-40D9B07A4A35

P478

Q43533227-9D81A694-9A30-4F88-AD18-6D276D4ED9E8

P50

Q43533227-65965F6C-B185-4712-8EA8-E15C8DA714EA

P577

Q43533227-A4253EC3-DCD4-4F6E-A682-45E3504C6A02

P698

Q43533227-E50FF6A5-5C7B-42CB-91AA-C6B667BE8FDE

P356

00005792-200203000-00003

P1433

P1476

Natural history of Fabry renal ...... mutations on clinical course.

@en

P2093

Gary J Murray

http://www.w3.org/2001/XMLSchema#string

Gheona Altarescu

http://www.w3.org/2001/XMLSchema#string

Howard A Austin Iii

http://www.w3.org/2001/XMLSchema#string

James E Balow

http://www.w3.org/2001/XMLSchema#string

Jane M Quirk

http://www.w3.org/2001/XMLSchema#string

Lev Goldfarb

http://www.w3.org/2001/XMLSchema#string

Mary H Branton

http://www.w3.org/2001/XMLSchema#string

Raphael Schiffmann

http://www.w3.org/2001/XMLSchema#string

Roscoe O Brady

http://www.w3.org/2001/XMLSchema#string

Sharda G Sabnis

http://www.w3.org/2001/XMLSchema#string

P304

122-138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00005792-200203000-00003

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey B. Kopp

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11889412

http://www.w3.org/2001/XMLSchema#string